License and Collaboration Agreement with ApolloBio Corp to Develop and Commercialize VGX-3100 in Greater China
| Target Company Name |
Inovio Pharmaceuticals Inc. |
|---|---|
| Target Country |
USA |
| Description | Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales. |
| Global M&A Advisory | Advisor to the seller |
